Torrent Pharmaceuticals registered a minor 0.99% dip in its net profit for the fourth quarter (Q4) of FY25, as earnings fell to Rs 498 crore from Rs 503 crore in the last quarter (Q3 FY25).
The local pharma company recorded its overall expenses at Rs 2,252 crore, up by almost 4.70% quarter-on-quarter (QoQ) and 4.99% year-on-year (YoY).
This increase in expenses was mainly spurred by increased expenditure in major areas. The material consumed cost rose 8.65% to Rs 402 crore, and employee benefit outflow surged 2.19% to Rs 561 crore.
Depreciation and amortization expenses inched up 1.01% to Rs 201 crore, and other expenses rose 4.46% to Rs 703 crore.
Even with the marginal decline in net profit, revenue of the company showed steady growth. Q4 FY25 operational revenue stood at Rs 2,959 crore, an increase of about 5.34% from Rs 2,809 crore in Q3.
Total income also increased by about 4.70% to Rs 2,941 crore from Rs 2,842 crore last quarter, according to the company's filing with the exchange.
Segmenting the market performance, the India business reported a 12% growth in revenue to Rs 1,545 crore, led by high performance across major therapy areas.
The US segment also grew by 15%, reporting Rs 302 crore in revenue. Germany reported a low 2% growth to Rs 286 crore.
Revenues from Brazil fell by 6% to Rs 351 crore, impacted by the weakening of the Brazilian Real.
As part of its succession plan, Torrent Pharmaceuticals made Aman Mehta, elder son of Torrent Group Chairman Samir Mehta, Managing Director from August 1. The company mentioned his roles in increasing market share, reenergizing cardiac and diabetes businesses, and leading the launch of consumer health business.
Furthermore, Torrent's board also proposed to seek shareholders' approval at the forthcoming Annual General Meeting (AGM) to raise up to Rs 5,000 crore through equity shares or convertible debt instruments like Qualified Institutional Placement (QIP) or alternative means.
Read also| Fortis Healthcare Reports 7.4% Decline in Q4 Profit Amid Rising Expenses
Read also| Saregama India Reports Over 50% Drop in Q4 Revenue, Net Profit Declines
